Surface Oncology Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$143M
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Surface Oncology's estimated annual revenue is currently $59.4M per year.(?)
  • Surface Oncology received $35.0M in venture funding in January 2015.
  • Surface Oncology's estimated revenue per employee is $618,927
  • Surface Oncology's total funding is $143M.

Employee Data

  • Surface Oncology has 96 Employees.(?)
  • Surface Oncology grew their employee count by 26% last year.
  • Surface Oncology currently has 4 job openings.

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients anti-tumor immune response. Our broad attack on the TME has the potential to convert patients non-responsive cold tumors into immune-active ones. We are committed to developing a pipeline of next-generation immunotherapies that deliver lasting benefits to patients suffering from cancer as quickly as possible. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. We utilize multiple antibody generation platforms and have established relationships with several best-in-class antibody technology partners. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment. The company has a strategic collaboration with Novartis and is supported by leading healthcare investors, including Atlas Venture, NEA, F-Prime, Lilly Ventures and Amgen Ventures.